Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis

Powell, Anna MD, MS*; Ghanem, Khalil G. MD, PhD; Rogers, Linda CRNP*; Zinalabedini, Ashley MS, CRNP*; Brotman, Rebecca M. PhD; Zenilman, Jonathan MD; Tuddenham, Susan MD, MPH

doi: 10.1097/OLQ.0000000000001063
Notes
Buy

A retrospective chart review characterized clinicians' use of maintenance intravaginal boric acid for women with recurrent vulvovaginal candidiasis or bacterial vaginosis. Average length of use was 13 months with high patient satisfaction and few adverse events. Prospective studies are needed to evaluate the efficacy of maintenance boric acid for these conditions.

We characterized clinician's use of maintenance boric acid for women with recurrent VVC or BV. Average length of use was 13 months with high patient satisfaction and few adverse events.

From the *Department of Obstetrics and Gynecology

Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine

Institute for Genome Sciences, University of Maryland, Baltimore, MD

Sources of Funding: S.T. is a consultant for Biofire diagnostics, S.T. is supported by K23AI125715.

Off-label use/unapproved drugs or products: boric acid is not FDA labeled for treatment of recurrent vulvovaginal candidiasis or bacterial vaginosis.

Conflicts of Interest: None declared.

Correspondence: Susan Tuddenham, MD, MPH, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center, 5200 Eastern Ave, MFL Center, Tower 378, Baltimore, MD, 21224. E-mail: studden1@jhmi.edu.

Received for publication July 12, 2019, and accepted August 25, 2019.

Online date: October 29, 2019

© Copyright 2019 American Sexually Transmitted Diseases Association